Evofem Biosciences News

10-Q: Quarterly report

SEC announcementMay 15 06:50 ET · Announcements

Express News | Evofem Biosciences Q1 Sales USD 3.603 Million

ReutersMay 15 06:50 ET

Express News | Evofem Biosciences Q1 Income From Operations USD -2.844 Million

ReutersMay 15 06:50 ET

Express News | Evofem Biosciences Q1 Pretax Profit USD -4.809 Million

ReutersMay 15 06:50 ET

Express News | Evofem Biosciences Q1 Operating Expenses USD 6.447 Million

ReutersMay 15 06:50 ET

Evofem Biosciences Announces Financial Results for the First Quarter of 2024

The company behind the hormone-free contraceptive Phexxi (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or...

PR NewswireMay 15 06:50 ET

Evofem Biosciences 1Q Loss $4.86M >EVFM

Evofem Biosciences 1Q Loss $4.86M >EVFM

Dow JonesMay 15 06:50 ET

Aditxt, Inc. Merger With Evofem Biosciences Falls Through

TipRanksMay 3 06:13 ET

Express News | Aditxt Said On April 26 Received Notice From Evofem That Evofem Was Exercising Its Right To Terminate Merger Agreement As Result Of Co's Failure To Provide Initial Parent Equity Investment

BenzingaMay 3 06:05 ET

Evofem Biosciences: Contractual Agreements Initiated and Terminated

TipRanksMay 2 17:42 ET

Evofem Strengthens Phexxi Intellectual Property With New Composition of Matter Patent From USPTO

-- Application allowed with broad method claims that are Orange Book-listable -- -- Once issued, this will be Evofem's fifth patent covering Hormone-Free "In the Moment" Contraceptive Phexxi in the U

PR NewswireApr 18 08:36 ET

Evofem Biosciences Issues Update With Latest Presentation

TipRanksMar 28 17:22 ET

Evofem Biosciences 4Q Loss/Shr 44c >EVFM

Evofem Biosciences 4Q Loss/Shr 44c >EVFM

Dow JonesMar 27 08:36 ET

Evofem Reports $18.2 Million of Phexxi Net Product Sales in 2023

-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth q

PR NewswireMar 27 08:36 ET

Press Release: Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI With Medi-Cal

Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal PR Newswire SAN DIEGO, March 20, 2024 -- Medi-Cal serves more than 15.4 million Californians --

Dow JonesMar 20 08:54 ET

For Women Using GLP-1 Receptor Agonists Who Take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel Is a Logical Solution to Help Prevent Unintended Pregnancy

Yahoo FinanceMar 7 07:54 ET

Express News | 'France Becomes First Country to Explicitly Enshrine Abortion Rights in Constitution' -Washington Post Report

Moomoo 24/7Mar 4 12:53 ET

Evofem Biosciences Achieves 2023 Prelim Net Product Sales of $18.1M to $18.3M

Seeking AlphaFeb 1 08:48 ET

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

PRNewswireFeb 1 08:00 ET

Evofem Biosciences(EVFM.US) Officer Sells US$4 in Common Stocks

$Evofem Biosciences(EVFM.US)$ Officer Zhang Yan sold 104 shares of Common Stocks on Jan 12, 2024 at an average price of $0.0385 for a total value of $4.Source: Announcement What is statement of change

moomoo NewsJan 12 17:25 ET